Role of Intranasal Topical Steroid in Pediatric Sleep Disordered Breathing and Influence of Allergy, Sinusitis, and Obesity on Treatment Outcome
Clinical and Experimental Otorhinolaryngology
; : 27-32, 2011.
Article
in En
| WPRIM
| ID: wpr-133456
Responsible library:
WPRO
ABSTRACT
OBJECTIVES: To evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleep-disordered breathing (SDB) patients. METHODS: A prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. All patients received 4-weeks course of mometasone furoate 100 microg/day treatment. They were evaluated at pretreatment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment. RESULTS: Total OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity (P=0.003, P=0.006). There was no complication after treatment of mometasone furoate. CONCLUSION: Pediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometasone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Pediatrics
/
Pregnadienediols
/
Quality of Life
/
Sinusitis
/
Skin
/
Sleep Apnea Syndromes
/
Adenoids
/
Prospective Studies
/
Administration, Topical
/
Treatment Outcome
Type of study:
Observational_studies
Limits:
Child
/
Humans
Language:
En
Journal:
Clinical and Experimental Otorhinolaryngology
Year:
2011
Type:
Article